TCTR20221227005已完成不适用
Safety and efficacy of continuous intravenous labetalol for blood pressure control in neurosurgery
/A0 个研究点目标入组 70 人开始时间: 2022年12月27日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 70
研究概览
简要总结
The efficacy and safety profiles of labetalol infusion suggest that this treatment is a promising option for controlling BP in neurosurgical patients.
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 Years 至 N/A (No limit)（—）
- 性别
- All
入选标准
- •Neurosurgical patients complicated with hypertension who received continuous intravenouslabetalol administration from November 1, 2021 to October 31, 2022
排除标准
- •1. pregnancy
- •2. patients who received other antihypertensive agents with labetalol
- •3. brain death
- •4. patients who received other drugs that affected to hemodynamics
- •5. patients who were ongoing triple H therapy during subarachnoid hemorrhage
- •6. patients with neurosurgical that were not related to brain, such as spinal disorders or peripheral nerve diseases
研究者
相似试验
Unknown
不适用
Prolonged Intravenous Infusion of β-lactam Antibiotics in Early Septic PatientsSepsisNCT05024565Qilu Hospital of Shandong University2,600
已完成
Unknown
Vedolizumab in ulcerative colitis Japanese patientsJPRN-jRCT1080225363Takeda Pharmaceutical Company Limited370
已完成
3 期
A Study of Effectiveness and Safety of Risperdal CONSTA Added to Usual Treatment in Patients With Bipolar Disorder Who Have Frequent Mood Episodes.Bipolar DisorderNCT00094926Johnson & Johnson Pharmaceutical Research & Development, L.L.C.275
已完成
3 期
Anifrolumab Asian PhIII Efficacy Study for Systemic Lupus Erythematosus (SLE)Active Systemic Lupus ErythematosusNCT04931563AstraZeneca277
已完成
3 期
Efficacy and Safety of Two Doses of Anifrolumab Compared to Placebo in Adult Subjects With Active Systemic Lupus ErythematosusActive Systemic Lupus ErythematosusNCT02446912AstraZeneca460